- Home
- ZIP vs ANNX Comparison
ZIP vs ANNX Comparison
Compare ZIP & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- ANNX
- Stock Information
- Founded
- ZIP 2010
- ANNX 2011
- Country
- ZIP United States
- ANNX United States
- Employees
- ZIP N/A
- ANNX N/A
- Industry
- ZIP Diversified Commercial Services
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- ZIP Consumer Discretionary
- ANNX Health Care
- Exchange
- ZIP Nasdaq
- ANNX Nasdaq
- Market Cap
- ZIP 365.3M
- ANNX 334.1M
- IPO Year
- ZIP 2021
- ANNX 2020
- Fundamental
- Price
- ZIP $4.23
- ANNX $2.76
- Analyst Decision
- ZIP Hold
- ANNX Strong Buy
- Analyst Count
- ZIP 4
- ANNX 4
- Target Price
- ZIP $4.88
- ANNX $13.00
- AVG Volume (30 Days)
- ZIP 856.2K
- ANNX 2.1M
- Earning Date
- ZIP 11-05-2025
- ANNX 11-10-2025
- Dividend Yield
- ZIP N/A
- ANNX N/A
- EPS Growth
- ZIP N/A
- ANNX N/A
- EPS
- ZIP N/A
- ANNX N/A
- Revenue
- ZIP $448,299,000.00
- ANNX N/A
- Revenue This Year
- ZIP N/A
- ANNX N/A
- Revenue Next Year
- ZIP $10.02
- ANNX N/A
- P/E Ratio
- ZIP N/A
- ANNX N/A
- Revenue Growth
- ZIP N/A
- ANNX N/A
- 52 Week Low
- ZIP $3.35
- ANNX $1.29
- 52 Week High
- ZIP $10.08
- ANNX $6.65
- Technical
- Relative Strength Index (RSI)
- ZIP 44.01
- ANNX 40.03
- Support Level
- ZIP $4.08
- ANNX $2.54
- Resistance Level
- ZIP $4.84
- ANNX $3.03
- Average True Range (ATR)
- ZIP 0.27
- ANNX 0.23
- MACD
- ZIP 0.01
- ANNX -0.06
- Stochastic Oscillator
- ZIP 26.36
- ANNX 15.57
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.